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a b s t r a c t
Young infants are less susceptible to severe episodes of malaria but the targets and mechanisms of pro-
tection are not clear. Cord blood antibodies may play an important role in mediating protection but many
studies have examined their association with the outcome of infection or non-severe malaria. Here, we
investigated whether cord blood IgG to Plasmodium falciparum merozoite antigens and antibody-
mediated effector functions were associated with reduced odds of developing severe malaria at different
time points during the first year of life. We conducted a case-control study of well-defined severe falci-
parum malaria nested within a longitudinal birth cohort of Kenyan children. We measured cord blood
total IgG levels against five recombinant merozoite antigens and antibody function in the growth inhibi-
tion activity and neutrophil antibody-dependent respiratory burst assays. We also assessed the decay of
maternal antibodies during the first 6 months of life. The mean antibody half-life range was 2.51 months
(95% confidence interval (CI): 2.19–2.92) to 4.91 months (95% CI: 4.47–6.07). The rate of decline of mater-
nal antibodies was inversely proportional to the starting concentration. The functional assay of antibody-
dependent respiratory burst activity predicted significantly reduced odds of developing severe malaria
during the first 6 months of life (Odds ratio (OR) 0.07, 95% CI: 0.007–0.74, P = 0.007). Identification of
the targets of antibodies mediating antibody-dependent respiratory burst activity could contribute to
the development of malaria vaccines that protect against severe episodes of malaria in early infancy.
 2016 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Plasmodium falciparum is a leading cause of childhood morbid-
ity and mortality with approximately 214 million cases and
438,000 deaths reported globally in the year 2015 (World Health
Organization, 2015). A disproportionate number of the malaria-
related deaths occur in sub-Saharan Africa with children under
the age of 5 years being at the highest risk of severe and life-
threatening malaria. Severe malaria in children manifests in three
overlapping clinical syndromes: severe anemia, impaired con-
sciousness and respiratory distress (Marsh et al., 1995). The pre-
sentation of these clinical features varies with host age and the
level of malaria transmission (Snow et al., 1994, 1997; Roca-
Feltrer et al., 2010). In high transmission areas, severe anemia is
predominant and affects mainly children aged less than
24 months, while in low-moderate transmission areas cerebral
malaria is the main clinical manifestation in older children
(O’Meara et al., 2008; Roca-Feltrer et al., 2010), causing high mor-
tality despite appropriate intervention. A significant proportion of
those who recover develop long-term neurological and cognitive
deficits (Idro et al., 2005).
Young infants in malaria endemic countries are relatively resis-
tant to severe malaria (Snow et al., 1998). Cord blood antibodies
are thought to confer protection against clinical episodes of
malaria (Edozien et al., 1962) but the evidence is far from clear
(Riley et al., 2001; Dobbs and Dent, 2016). Although passively
transferred cord blood IgG was shown to reduce parasitemia and
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clinical symptoms in one study (Edozien et al., 1962), the targets of
such antibodies have yet to be identified (Hviid and Staalsoe,
2004). Importantly, although many studies have investigated
maternal antibodies in relation to the risk of infection, clinical or
febrile malaria, none have focused on severe malaria as the end-
point of interest.
We designed a case-control study of severe malaria nested
within a longitudinal birth cohort of infants who were monitored
for episodes of well-characterised severe malaria (Lundblom
et al., 2013; Murungi et al., 2016). We identified the sub-group of
infants for whom a cord blood sample was available. We measured
cord blood plasma total IgG levels against five recombinant P. fal-
ciparum merozoite antigens and its functional activity in the
growth inhibition activity (GIA) and antibody-dependent respira-
tory burst (ADRB) assays (Llewellyn et al., 2015; Murungi et al.,
2016). We investigated factors that were likely to have an influ-
ence on these antibody measures and assessed the decay of
antigen-specific cord blood IgG over the first 6 months of life.
Finally we investigated whether antibody levels and function in
cord blood were associated with reduced odds of developing sev-
ere falciparum malaria at different time points during the first year
of life when maternal antibodies are likely to persist.
2. Materials and methods
2.1. Study site and population
The study was conducted in Kilifi County, on the Kenyan coast.
The area experiences two seasonal peaks in malaria transmission
(May to August and October to November). The study setting and
study population are described in detail elsewhere (Lundblom
et al., 2013; Murungi et al., 2016). Briefly, following informed con-
sent, infants born to mothers who delivered at Kilifi County Hospi-
tal (KCH) or those attending the immunisation clinic during the
first month of life were recruited into a birth cohort (Kilifi Birth
Cohort, KBC) (n = 5,949) set up between 2001 and 2008 to study
the risk factors of invasive pneumococcal disease in young chil-
dren. As the study was primarily set up to study pneumococcal dis-
ease, malaria-specific indices such as intermittent preventive
treatment during pregnancy (iPTp) and bed net usage were not
recorded. The children were followed up quarterly at the Outpa-
tient Department of KCH until 2 years of age. During the quarterly
visits, a blood sample was collected and thick and thin blood
smears prepared for detection of parasites by microscopy. In the
event of an illness outside the scheduled 3-monthly visits, parents
were advised to seek care at KCH and the children were treated
according to national guidelines. Children who were admitted to
hospital were identified using a unique number that linked their
clinical, demographic and laboratory information.
2.1.1. Study design
We designed a matched case-control study of well-defined sev-
ere malaria cases that included all infants enrolled into the KBC
and longitudinally monitored as described in Section 2.1. We
included cases admitted to hospital between April 2002 and Jan-
uary 2010. Cases were individually matched to a maximum of
three controls by age, date of sample collection and area of resi-
dence. Controls were selected from KBC participants who did not
present to KCH with severe malaria during the 8-year monitoring
period. A total of 61 severe malaria cases were identified and these
were individually matched to 161 controls (Lundblom et al., 2013;
Murungi et al., 2016). The data presented here are drawn from the
subset of these children who were recruited at birth and had a 2 ml
venous blood sample taken from the umbilical vein (n = 130). Fol-
lowing informed consent, baseline information (age of the mother,
number of previous pregnancies, antenatal clinic attendance, ges-
tation period, birth weight and gender of the infant) and a cord
blood sample were obtained (Table 1). We also analyzed samples
collected at 3 and 6 months of age from the cases and controls to
determine the dynamics of decay of maternal antibodies.
2.1.2. Severe malaria case definition
Inclusion criteria for severe malaria cases were admission to
hospital between April 2002 and January 2010 with detectable par-
asites by microscopy and one of the following symptoms: (i)
impaired consciousness (Blantyre Coma Score <5), (ii) chest
indrawing or deep breathing or (iii) severe anemia (Hb <5 g/dL).
2.1.3. Detection of asymptomatic infections
Detection of malaria parasites in the samples collected every
3 months was performed retrospectively by microscopy and PCR
as previously described (Lundblom et al., 2013). Briefly, thick and
thin blood films were stained with Giemsa and examined by light
microscopy. Parasite densities were determined as the number of
parasites per 8,000 white blood cells per ll of blood. The preva-
lence of submicroscopic infections was determined by PCR ampli-
fication of the polymorphic block 3 region of the merozoite surface
protein 2 (msp2) gene followed by capillary electrophoresis
(Liljander et al., 2009).
2.2. Recombinant P. falciparum merozoite antigens
We measured total IgG titres to a panel of five recombinant
merozoite antigens that are currently being assessed in clinical,
pre-clinical, animal model and in vitro studies as potential blood-
stage malaria vaccine candidates. Reactivity to schizont extract
was used as a marker of previous exposure to infection. Full-
length apical membrane antigen (AMA)1 (3D7 P. falciparum strain)
Table 1
Baseline characteristics of the mothers and their infants at enrolment in the study.
Cases (n = 32) Controls (n = 98) P
valuea
Median maternal age in years
(range)b
27.8 (14.9–44.0) 25.4 (14.7–48.0) 0.26
Median no. of previous
pregnancies (range)c
5 (0–8) 4 (0–13) 0.25
Gender female, n/Total (%) 15/32 (46.8%) 47/98 (47.9%) 0.91
Median gestation weeksd
(range)e
38 (23–42) 38 (28–50) 0.82
Median birth weight in
kilograms (range)f
2.7 (1.8–4.3) 2.8 (1.6–3.8) 0.68
Antenatal clinic attendance, n/
Total
recorded (%)
12/13 (92.3%) 43/45 (95.5%) 0.64
Year of birth, n (%)
2002 15 (46.8%) 40 (40.8%) 0.56
2003 9 (28.1%) 21 (21.4%)
2004 6 (18.7%) 31 (31.6%)
2005 2 (6.2%) 4 (4.0%)
2006 0 (0%) 2 (2.0%)
Season of birth
Dry seasong 20 (62.5%) 58 (59.1%) 0.74
Rainy seasonh 12 (37.5%) 40 (40.8%)
a The Mann–Whitney U and chi-square tests were applied for comparisons of
continuous variables and proportions, respectively, among the cases and controls.
b Data were available from mothers of 32 (100%) severe malaria cases and 96
(97%) controls.
c Data were recorded from mothers of 22 (68%) cases and 74 (75%) controls.
d Gestation age was assessed based on the date of last menstrual period (LMP) or
symphyseal-fundal height of the uterus, converted to weeks using dating charts.
e Data were recorded from mothers of 13 (40%) cases and 45 (45%) controls.
f Data were available for 16 (50%) children who developed severe malaria and 50
(51%) controls.
g The dry season occurs in January–March.
h The rainy season occurs in May–August and October–November.
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was expressed as a Histidine (His)-tagged protein in Pichia pastoris
(Dutta et al., 2002), MSP-2 (Dd2 P. falciparum strain) was expressed
as a glutathione S-transferase (GST)-fusion protein in Escherichia
coli (Taylor et al., 1995) and MSP-3 (3D7) as a maltose binding pro-
tein (MBP)-fusion protein also in E. coli (Polley et al., 2007). The
C-terminal 19 kDa fragment of MSP-1 (MSP-119) (Wellcome) and
a fragment of P. falciparum reticulocyte-binding homolog 2 (PfRh2
(3D7)) were expressed as GST- (Burghaus and Holder, 1994) and
His-tagged fusion proteins (Reiling et al., 2010), respectively, in
E. coli. A P. falciparum schizont lysate based on the A4 parasite line
was prepared by sonicating mature schizont stages (Ndungu et al.,
2002).
2.3. ELISA
Total IgG responses against the P. falciparummerozoite antigens
described in Section 2.2 were simultaneously measured by multi-
plex ELISA as described previously (Rono et al., 2013). We also
measured IgG to parasite schizont lysate (3D7) using a standard
ELISA protocol (Murungi et al., 2016). Eleven serial dilutions of a
purified IgG preparation obtained from Malawian adults (Taylor
et al., 1992) were included for every antigen tested to obtain a
standard dilution curve that allowed the conversion of median flu-
orescence intensity (MFI) readings to arbitrary antibody concentra-
tions. A pool of plasma obtained from Kilifi adults was included in a
single well on each plate as a positive control to allow for standard-
isation of day-to-day and plate-to-plate variation. Twenty plasma
samples obtained from UK adults who had not been exposed to
malaria were also included as negative controls for each antigen
tested. Seropositivity for antibody titres was defined as ELISA O.
D. value above the mean + 3 S.D. of the 20 malaria non-exposed
UK plasma samples. All samples were assayed in duplicate and
for those that had a coefficient of variation (CV) greater than
20%, the assays were repeated.
2.4. Assays of antibody function
The assays of GIA and ADRB activity were performed as previ-
ously described (Murungi et al., 2016) using cord blood plasma
samples. The GIA assay has been used to assess the vaccine efficacy
of blood-stage vaccine candidates both in animal models and clin-
ical studies (Duncan et al., 2012). The assay has also been associ-
ated with protection from clinical malaria in some studies
(Crompton et al., 2010; Rono et al., 2012) but this has not been a
consistent finding. The ADRB assay has also been shown to corre-
late with protection against clinical episodes of malaria in field
studies (Joos et al., 2010).
2.4.1. Assay of GIA
Cord plasma were dialyzed in 1 X PBS using 20 kDa MWCOmini
dialysis units and incubated at 56 C for 30 min to inactivate com-
plement proteins. Highly synchronous trophozoite stage parasites
from the 3D7 P. falciparum strain (0.3–0.5% parasitemia, 1% hema-
tocrit) were added to individual wells, followed by the dialyzed
plasma at a ratio of 1:10. The plates were incubated in a humidified
chamber containing 5% CO2, 5% 02 and 90% N2 for 80 h. Ten micro-
liters of culture medium were added to each well after the first
growth cycle. A positive and negative control well containing
10 mg/ml of purified Malaria Immune Globulin (MIG) and a pool
of plasma from UK adults, respectively, were included. After two
cycles, the parasites were stained with 10 lg/ml of ethidium bro-
mide for 30 min, washed with 1 X PBS and acquired on an FC500
(Beckman Coulter, USA) flow cytometer.
2.4.2. Parasite culture and isolation of parasitophorous vacuole
enclosed membrane structures (PEMS)
Plasmodium falciparum 3D7 parasite cultures were maintained
at <10% parasitemia and 2% hematocrit. Highly synchronous
mature trophozoite stages were enriched by magnetic separation
and allowed to mature into early schizont stages. Thereafter, a pro-
tease inhibitor (trans-epoxysuccinyl-L-leucylamido (4-guanidino)
butane (E-64)) was added to allow development into late schizonts
without rupture. The schizonts were pelleted, resuspended in 1 X
PBS and stored at 20 C.
2.4.3. Isolation of human polymorphonuclear cells (PMNs)
Whole blood samples from healthy donors were collected into
heparin tubes, layered onto Ficoll-Histopaque 1077 (Sigma, Ger-
many) and centrifuged at 600g for 15 min at room temperature
(RT). The pellet containing PMNs and red blood cells (RBCs) was
resuspended in 3% dextran solution and incubated for 30 min at
RT in the dark. Thereafter, the supernatant was carefully removed
and centrifuged at 500g for 7 min. Residual RBCs were lysed using
ice cold 0.2% NaCl followed by 1.6% NaCl. PMNs were washed in
PMN buffer (Hank’s Balanced Salt Solution (HBSS) supplemented
with 0.1% BSA and 1% D-(+)-glucose) and resuspended in PMN buf-
fer at a concentration of 1x107 PMNs/ml.
2.4.4. ADRB assay
The ADRB assay was performed as previously described
(Llewellyn et al., 2015; Murungi et al., 2016). Briefly, PEMS were
thawed and coated overnight onto individual wells of Nunc opaque
MaxiSorp 96-well plates (Thermo Scientific, USA) at 18.5  105/ml.
Following three washes with 1 X PBS, the plates were blocked and
incubated with plasma (1:50) for 1 h at 37 C. The plates were
washed and 50 ll of PMNs (1  107 PMNs/ml) added, followed by
50 ll of isoluminol (0.04 mg/ml). Chemiluminescence was mea-
sured for 1 s every 2 min over an hour. Control wells containing
a pool of UK adult plasma and a pool of plasma from Kilifi adults
were included in each plate. Readings were expressed relative to
those obtained from the pool of plasma from Kilifi adults.
2.5. Statistical analysis
All analyses were performed using Stata 13.0 (StataCorp, Texas,
USA) and GraphPad prism Version 6 (GraphPad Software, Inc). A
linear regression model that included an indicator of the case-
control status was used to determine the influence of maternal
age, parity, birth weight, year of birth, season of birth and gestation
period on the levels of specific antibodies and antibody function.
The Benjamini-Hochberg method was used to adjust for the false
discovery rate. The rate of antibody decay was determined using
a longitudinal mixed-effects model (Amanna et al., 2007; Fowkes
et al., 2012). The model accounts for repeated measurements from
an individual and was fitted to the log10-transformed values of the
antibody titres collected at ages 0, 3 and 6 months. To assess the
natural decay of maternal IgG in the absence of boosting due to
infection, we excluded children that had antibody titres boosted
at 3 months of age compared with baseline titres as well as those
with boosted titres at 6 months of age compared with titres at
3 months of age. Half-life estimates were calculated using the
equation:
T1=2 ¼ ln 2=m
where T1/2 is the estimated half-life and m is the slope component
of the mixed-effects model (Amanna et al., 2007; Kinyanjui et al.,
2007; Ochola et al., 2009; Fowkes et al., 2012). A conditional logistic
regression model was used to investigate the association between
antibody levels and function with the odds of developing a severe
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malaria episode at different time points over the first year of life.
Antibodies were fitted as categorical variables in the model based
on a cut-off for seropositivity (defined as an ELISA O.D. value above
the mean + 3 S.D. of 20 European plasma samples). This cut-off was
also used to define the seroprevalence of merozoite-specific anti-
bodies. The Wald test was used to estimate the statistical signifi-
cance of categorical covariates. Seropositivity for ADRB was
defined as a cut-off above the mean + 3 S.D. of 20 European plasma
samples whereas the GIA cut-off for positivity was defined as being
above the median GIA level of the cord plasma samples assayed
(Rono et al., 2012; Murungi et al., 2016). P < 0.05 was considered
statistically significant.
3. Results
3.1. Severe malaria episodes
Of the 222 children recruited to the matched case-control study
of severe malaria described previously (Lundblom et al., 2013;
Murungi et al., 2016), 130/222 (58.5%) were born at KCH and had
a 2 ml cord blood sample drawn at birth. Of these, 32 developed
severe malaria; 12 (37%), seven (21%) and six (18%) of whom pre-
sented to hospital with respiratory distress, impaired conscious-
ness (BCS <5) and severe malaria anemia (Hb <5 g/dL),
respectively. Six infants (18%) presented with two overlapping sev-
ere malaria syndromes and one (3%) with all three syndromes. Of
the 32 cases, five (15.6%) occurred during the first 6 months of life,
12 (37.5%) within 9 months and 16 (50%) before 12 months. The
remaining 16 cases (50%) occurred beyond the age of 1 year. No
cases occurred in the first 4 months of life (Fig. 1). The median
age of admission with severe malaria was 12.5 months (range
5.6–74.0). The remaining 98/130 (75%) children made up the con-
trols, 20 of whom had a history of admission to hospital with gas-
troenteritis and lower respiratory tract infections. None of the
controls was admitted with non-severe malaria.
Twenty-seven out of 130 (20.0%) acquired asymptomatic
P. falciparum infections as measured by PCR or microscopy in the
quarterly samples collected up to 2 years of age. Of these, 11/32
(34%) were identified among the children who subsequently devel-
oped severe malaria and 16/98 (16%) among the controls.
3.2. Prevalence of antibodies and functional indices of immunity
There was no significant difference in cord blood seropreva-
lence (Fig. 2A) or levels of antibodies (Supplementary Fig. S1)
between the cases of severe malaria (n = 32) and controls (n = 98)
for all antigens. Among the cases, the seroprevalence against sch-
izont lysate, AMA1(3D7), MSP-2(Dd2), MSP-3(3D7), MSP-119 and
PfRh2 was 98%, 93%, 87% 69%, 46% and 33%, respectively, compared
with 100%, 93%, 90%, 68%, 43% and 37% among the controls
(Fig. 2A). The median GIA level was 28.9% (range 25.9 to 99.4)
with no statistically significant difference between the cases and
controls (29.2% and 28.9%, respectively) (Fig. 2B). Similarly, the
median ADRB level was 0.4 indexed relative light units (RLU)
(range 0.1–1.65) and the median levels were comparable among
the cases and controls (0.3 and 0.4, respectively) (Fig. 2B). We pre-
viously published threshold concentrations of antibodies to speci-
fic antigens that appeared to be necessary for protection against
clinical episodes of malaria (Murungi et al., 2013; Rono et al.,
2013). The prevalence of antibodies at threshold concentrations
in cord blood was low and importantly did not differ between sev-
ere malaria cases and controls; AMA1, 6.2% versus 6.1%; MSP-2,
21.8% versus 18.3% and MSP-3, 18.7% versus 17.7%, respectively.
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Table 2
Factors that influence the levels and function of merozoite-specific antibodies in cord blood plasma.
Predictor (No. cases,
No. of controls)
Anti-AMA P
P⁄
Anti-MSP-2 P
P⁄
Anti-MSP-3 P
P⁄
Anti-MSP-119 P
P⁄
Anti-Rh2 P
P⁄
GIA P
P⁄
ADRB P
P⁄
Maternal factors
Age (32, 96) 0.01 (0.03, 0.007) 0.23
0.33
0.008 (0.007, 0.02) 0.31
0.40
0.01 (0.001, 0.03) 0.05
0.11
0.006 (0.01, 0.02) 0.60
0.98
0.0006 (0.01, 0.01) 0.93
0.61
0.94 (0.07, 1.81) 0.03
0.10
0.01 (0.003, 0.01) 0.004
0.02
Gravidity
Primigravid (2, 9)
Multigravid (20, 65)
0.27 (0.75, 0.20) 0.25
0.56
0.19 (0.22, 0.62) 0.35
0.56
0.06 (0.55, 0.41) 0.78
0.98
0.01 (0.59, 0.55) 0.95
0.56
0.25 (0.64, 0.14) 0.21
0.98
0.72 (21.15, 22.59) 0.94
0.98
0.07 (0.09, 0.24) 0.36
0.56
Gestation (weeks)
Full Term (10, 35)
Preterm (3, 10)
0.16 (0.23, 0.57) 0.40
0.56
0.26 (0.13, 0.65) 0.18
0.33
0.31 (0.14, 0.77) 0.17
0.33
0.18 (0.41, 0.79) 0.53
0.70
0.07 (0.31, 0.46) 0.71
0.61
15.01 (6.56, 36.59) 0.16
0.33
0.15 (0.003, 0.31) 0.05
0.33
Infant factors
Gender
Male (17, 51)
Female (15, 47)
0.13 (0.13, 0.41) 0.31
0.71
0.02 (0.21, 0.26) 0.83
0.89
0.04 (0.30, 0.21) 0.72
0.83
0.13 (0.18, 0.44) 0.41
0.71
0.09 (0.30, 0.10) 0.34
0.71
6.25 (6.09, 18.59) 0.31
0.71
0.03 (0.13, 0.06) 0.54
0.77
Birth weight
(16. 50)
0.09 (0.40, 0.20) 0.51
0.89
0.01 (0.26, 0.30) 0.90
0.90
0.06, 0.37, 0.25) 0.70
0.90
0.04 (0.47, 0.37) 0.82
0.89
0.09 (0.18, 0.38) 0.48
0.90
10.81 (25.63, 4.00) 0.14
0.89
0.01 (0.13,0.09) 0.75
0.89
Environmental factors
Season
Dry season
(20, 58)
Wet season
(12, 40)
0.09 (0.36, 0.18) 0.52
0.89
0.03 (0.20, 0.28) 0.76
0.89
0.04 (0.30, 0.21) 0.74
0.89
0.40 (0.72, 0.08) 0.013
0.07
0.06 (0.27, 0.14) 0.53
0.89
0.25 (12.42, 12.92) 0.96
0.97
0.01 (0.08,0.11) 0.75
0.89
Year of Birth
2002 (15, 40)
2003 (9, 21)
2004 (6, 31)
2005 & 2006 (2, 6)
0.10 (0.45, 0.25)
0.12 (0.45, 0.21)
0.10 (0.69, 0.48)
0.88
0.91
0.05 (0.25, 0.36)
0.14 (0.43, 0.14)
0.29 (0.80, 0.22)
0.45
0.87
0.01 (0.31, 0.34)
0.03 (0.35, 0.27)
0.41 (0.96, 0.14)
0.51
0.87
0.15 (0.25, 0.56)
0.05 (0.33, 0.44)
0.13 (0.82, 0.55)
0.83
0.91
0.04 (0.31, 0.23)
0.01 (0.27, 0.23)
0.12 (0.32, 0.58)
0.91
0.91
23.35 (8.65, 38.06)
22.36 (8.31, 36.40)
22.34 (46.53, 1.85)
0.0001
0.0007
0.13 (0.01, 0.26)
0.20 (0.08, 0.32)
0.06 (0.14,0.27)
0.006
0.01
The values indicated in the table are coefficients (95% confidence intervals) and P values of the change in relative antibody concentrations or function per unit change in continuous covariate or compared with the reference group,
for categorical covariates. Coefficients less than, greater than or equal to zero indicate a decrease, increase or no overall change in antibody concentrations per unit increase in the explanatory variable, respectively. P < 0.05 was
considered statistically significant. P⁄ are adjusted P values after correction for multiple testing. Bold indicates P values that are statistically significant.
AMA, apical membrane antigen; MSP, merozoite surface protein; PfRh, Plasmodium falciparum reticulocyte-binding homolog; GIA, growth inhibition activity; ADRB, neutrophil antibody-dependent respiratory burst.
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3.3. Factors that influence the level and function of antibodies
measured in cord blood plasma
We used a linear regression model to determine which factors
were positively or negatively correlated with increasing antibody
levels and function in cord blood plasma (Table 2). Maternal age
was positively associated with higher GIA and ADRB levels (regres-
sion coefficient 0.94 (0.07, 1.81), P = 0.03 and 0.01 (0.003, 0.01),
P = 0.004, respectively) (Table 2) and (Supplementary Fig. S2) but
not with antibodies to individual antigens (Table 2). However, this
result remained significant for ADRB levels only after adjustment
for multiple comparisons (P = 0.02). Surprisingly, we observed an
increase in GIA and ADRB levels over the duration of recruitment
(2002–2006) (Supplementary Fig. S3), a period marked by contin-
uous decline in malaria transmission intensity (Okiro et al., 2007;
O’Meara et al., 2008). Other factors such birth weight, parity, ges-
tation period, season and gender of the child did not significantly
influence the levels of specific antibodies measured in cord blood
or their functional activity (Table 2).
3.4. Dynamics of the decay of antibody titres
The decay rate of antibodies to specific antigens was deter-
mined using a longitudinal mixed-effects model (Amanna et al.,
2007; Fowkes et al., 2012). A regression line was fitted through
log10 transformed antibody titres for both cases and controls aged
less than 6 months. All the index samples were collected prior to
the severe malaria episode. To assess the decay of antibodies in
the absence of boosting of P. falciparum infection, we excluded
results from five cases and five controls who had detectable para-
sites at either month 3 or 6. In addition, all samples from individ-
uals whose antibody titres at 3 months of age were higher than
cord titres were excluded and for those whose titres at 6 months
were higher than month 3, only the result for the 6-monthly sam-
ple was excluded. A total of 56 (43%) samples (12 cases and 44 con-
trols) were excluded in the analysis. The mean half-life range was
2.51 months (95% confidence interval (CI): 2.19–2.92) to
4.91 months (95% CI: 4.47–6.07) (Table 3). There was no significant
difference in the mean decay rate of antibodies against AMA1
(3D7), MSP-2 (Dd2) and MSP-3 (3D7). However, anti-MSP-119
and PfRh2 antibodies had a significantly longer mean half-life com-
pared with other antigens tested (mean half-life 4.27 months
(3.85–5.02) and 4.91 months (4.47–6.07, respectively) (Table 3).
The rate of decay of antibodies did not differ between infants
who subsequently became cases and those that were controls
although the numbers in each group were limited and precluded
the ability to detect any significant differences (Supplementary
Table S1).
Next, we tested the rates of decay of antibodies according to the
quartile distribution of cord titres. The titres were divided into
quartiles and the decay rate of antibodies within each quartile
assessed as shown in Fig. 3. Titres in the highest quartile (4th quar-
tile) decayed most rapidly, followed by those in the 3rd, 2nd and
1st quartiles, in that order (Fig. 3) for all antigens tested with the
exception of AMA1 (Fig. 3A). For example, the decay rate for
MSP-2 (Dd2) antibodies was 0.14, 0.22, 0.23 and 0.31 log10 AU
reduction per month in the 1st, 2nd, 3rd and 4th cord quartiles,
respectively (Fig. 3B). The average rate of decay and 95% CI esti-
mates across the different quartiles for all antigens tested are
shown in Fig. 3F–J.
3.5. Relationship between antibodies and odds of developing severe P.
falciparum malaria
We evaluated the relationship between cord antibody titres and
their functional activity (GIA and ADRB) with the odds of develop-
ing severe malaria at different time points after birth (6, 9 and
12 months of age) (Fig. 4). Although the median age of admission
with severe malaria was 12.5 months (range 5.6–74.0), we
excluded the cases of severe malaria that occurred beyond
12 months (n = 16), as it was highly unlikely that cord blood anti-
bodies were responsible for protection. Thus, we analysed samples
from a total of 16 severe cases admitted to hospital during the first
12 months of life. These were individually matched to four controls
per case based on date of birth. Three cases were born a few days
apart and were therefore matched to a similar set of four controls.
Seropositivity for antibody titres and ADRB were defined as a
cut-off above the mean + 3 S.D. of 20 European plasma samples
whereas the GIA cut-off for positivity was defined as being above
the median GIA level of the cord plasma samples (Rono et al.,
2012; Murungi et al., 2016). Of the 130 children who had a cord
plasma sample, 26/32 (81%) and 16/32 (50%) severe malaria cases
were seropositive for ADRB and GIA, respectively. Of the 16 severe
malaria cases admitted to hospital during the first 12 months of
life, 2/5 (40%), 8/12 (66%) and 12/16 (75%) were seropositive for
ADRB during the first 6, 9 and 12 months of life, respectively, com-
pared with 18/20 (90%), 43/47 (91%) and 50/55 (90%) of controls.
On the other hand, 3/5 (60%), 8/12 (66%) and 9/16 (56%) of cases
and 12/18 (66%), 29/44 (65%) and 36/59 (70%) of controls had anti-
bodies above the median GIA levels during the first 6, 9 and
12 months of life, respectively.
There was a positive and significant correlation between cord
blood antibodies to all the antigens tested in both the severe
malaria cases and controls with the exception of antibodies against
MSP-2 and PfRh2 (rho = 0.13, P = 0.19) and MSP-3 and PfRh2
(rho = 0.16, P = 0.10) among the controls but not cases (Supplemen-
tary Fig. S4). Assays of GIA and ADRB activity were significantly
correlated among the controls (rho = 0.34, P = 0.0006) but not the
cases (rho = 0.0009, P = 0.99) (Supplementary Fig. S4). There
was only limited co-linearity between the different indices of
immunity that we measured (VIFs <2; mean VIF = 1.77 and 1.70
in the cases and controls, respectively). We observed a significant
increase in ADRB levels (Kruskal–Wallis test P < 0.009) but not
GIA activity (Kruskal–Wallis test P = 0.058) with increase in the
breadth of merozoite-specific cord blood antibodies (seropositivity
against the number of antigens tested) (Supplementary Fig. S5).
Antibody titres to all antigens tested were not associated with pro-
tection against severe malaria at the different time points after
birth (Fig. 4A). Children who were positive for ADRB had signifi-
cantly reduced odds of developing severe malaria during the first
6 months of life (OR 0.07 (95% CI: 0.007–0.74) P = 0.007) and this
association remained strong and significant until 9 months of age
(OR 0.16 (95% CI: 0.02–0.92, P = 0.041) but was lost thereafter
(Fig. 4B). In contrast, GIA was not associated with protection at
any time point (Fig. 4B). We have previously demonstrated that
children who had antibodies that were capable of inhibiting
Table 3
The overall rate of decay and antibody half-lives of maternally transferred antibodies
against specific merozoite antigens.
Antigen Rate of decaya (95% CI) Antibody half-life in
months (95% CI)
AMA1 (3D7) 0.222 (0.243, 0.201) 3.121 (2.851–3.447)
MSP-2 (Dd2) 0.243 (0.276, 0.210) 2.851 (2.510–3.296)
MSP-3 (3D7) 0.276 (0.316, 0.237) 2.510 (2.193–2.924)
MSP-119 0.162 (0.180, 0.138) 4.277 (3.850–5.021)
PfRh2 0.141 (0.155, 0.114) 4.914 (4.470–6.078)
CI, Confidence interval; AMA, apical membrane antigen; MSP, merozoite surface
protein; PfRh, Plasmodium falciparum reticulocyte-binding homolog; AU, arbitrary
units.
a Decay rate (log10 AU/month).
158 L.M. Murungi et al. / International Journal for Parasitology 47 (2017) 153–162
P<0.001
P<0.001
P<0.001
P=0.014
P=0.027
0
.
1
.
2
.
3
.
4
An
tib
od
y d
ec
ay
 ra
te
1st 2nd 3rd 4th
Cord titre quartiles
P<0.001
P<0.001
P<0.001
P<0.001
P<0.001
P<0.001
-
.
2
-
.
1
0
.
1
.
2
An
tib
od
y d
ec
ay
 ra
te
1st 2nd 3rd 4th
Cord titre quartiles
P<0.001 P<0.001 P<0.001
P<0.001
P<0.001
P<0.001
-
.
2
-
.
1
0
.
1
.
2
An
tib
od
y d
ec
ay
 ra
te
1st 2nd 3rd 4th
Cord titre quartiles
P=0.02
P=0.008
P<0.001
P=0.012
P=0.03
0
.
1
.
2
.
3
An
tib
od
y d
ec
ay
 ra
te
1st 2nd 3rd 4th
Cord titre quartiles
P<0.001
P<0.001
P<0.001
P=0.003
0
.
1
.
2
.
3
An
tib
od
y d
ec
ay
 ra
te
4th2nd 3rd1st
Cord titre quartiles
0.01
0.1
1
10
100
MS
P-
2(D
d2
)AU
0 3 6
Age (months)
0.01
0.1
1
10
100
AM
A1
(3D
7)A
U
0 3 6
Age (months)
0.01
0.1
1
10
100
MS
P-
3(3
D7
)AU
0 3 6
Age (months)
0.01
0.1
1
10
100
MS
P-
1 1
9 A
U
0 3 6
Age (months)
M
S
P
-1
1
9 
A
U
0.01
0.1
1
10
100
Pf
Rh
2 A
U
0 3 6
Age (months)
Pf
Rh
2 
AU
A
B
C
D
E
.
3
F
G
H
I
J
Fig. 3. Decay of cord blood IgG relative to the initial concentration. Scatter plots of antibody titres to (A) apical membrane antigen 1 (AMA1) (3D7 Plasmodium falciparum
strain), (B) merozoite surface protein 2 (MSP-2) (Dd2 P. falciparum strain), (C) MSP-3 (3D7) (D) MSP-119 and (E) P. falciparum reticulocyte-binding homolog 2 (PfRh2), showing
the decay rates relative to the initial (cord blood) titres. Closed squares and circles represent the cases and controls, respectively. Antibody titres in cord blood were divided
into quartiles and regression lines fitted for each quartile as shown in maroon (1st quartile), blue (2nd quartile), red (3rd quartile) and green (4th quartile) using data collected
during 6 months of follow-up from birth. The decay rates and 95% confidence intervals (CIs) of cord blood titres (y-axis) according to the different quartile levels (x-axis) are
shown for the antigens tested (F) AMA1 (3D7), (G) MSP-2 (Dd2), (H) MSP-3 (3D7), (I) MSP-119 and (J) PfRh2. P values <0.05 indicate differences between regression
coefficients (decay rates) that were statistically significant.
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growth of parasites and mediating release of reactive oxygen spe-
cies by neutrophils had significantly reduced odds of developing
severe malaria during the first year of life (Murungi et al., 2016).
Here, a combination of the two functional assays was not associ-
ated with protection against severe malaria (Fig. 4B).
4. Discussion
We designed a case control study of severe malaria nested
within a longitudinally monitored birth cohort. This design pro-
vided a unique opportunity to determine whether antibodies pre-
sent in cord blood were associated with a reduced risk of severe
malaria during infancy. We found that cord blood IgG in the assay
of ADRB activity was significantly associated with lower odds of
developing severe malaria. This association was only observed
for severe malaria cases occurring within 9 months of birth and fits
expectations of the half-life of passively transferred maternal anti-
bodies (White et al., 2014). Cord blood IgG against merozoite anti-
gens tested was not associated with protection and the half-life
ranged from between 2.5 to 4.9 months for the antigens tested.
Interestingly, antibody decay rates were inversely proportional to
the initial titres present in cord blood.
The ADRB assay has been assessed in a limited number of stud-
ies (Joos et al., 2010; Kapelski et al., 2014; Llewellyn et al., 2015)
and has been shown to correlate with protection against clinical
episodes of malaria in some of these investigations (Joos et al.,
2010). No studies have evaluated the effect of cord blood antibod-
ies capable of inducing ADRB with subsequent risk of malaria in
early infancy and we propose that our study is unique in this
respect. The strong correlation between ADRB levels and breadth
of responses to merozoite antigens suggest that multiple targets
mediate the overall ADRB activity. On the other hand, the weak
correlation between GIA and ADRB highlight the distinct mecha-
nisms of actions measured by these assays and suggest that the
merozoite targets may be different or antibodies to the targets that
mediate these mechanisms were absent. GIA was not associated
with protection against severe malaria.
Our study differs from previously published reports that inves-
tigated the protective role of maternal antibodies against the out-
comes of infection and/or clinical or febrile malaria (reviewed in
Riley et al., 2001; Dobbs and Dent, 2016). None of the previous
studies focused on severe malaria as an endpoint. Furthermore,
the duration of observation in previous analyses has varied ranging
from between 5 months (Riley et al., 2000) to 2 years (Kangoye
et al., 2014). Our present analysis supports the view that maternal
antibodies against merozoite antigens are unlikely to persist at
high titres beyond 5 months (Kangoye et al., 2016; White et al.,
2014) and that this relatively short period during which antibodies
are actually available may account for the inconsistency in findings
from studies investigating the protective role of maternal antibod-
ies (reviewed in Riley et al., 2001; Dobbs and Dent, 2016). Impor-
tantly, whether the end-point of such studies is severe or
uncomplicated malaria, clinical episodes as a whole are relatively
rare in children under 6 months of age despite the fact that they
frequently harbor low-level asymptomatic infections (Wagner
et al., 1998; D’Alessandro et al., 2012). Thus whilst antibodies
may play a protective role, the lack of sufficient cases during this
period limits the analysis and will require very large studies.
A key and interesting finding in our study was that antibody
decay rates are inversely proportional to the initial titres present
in cord blood, a finding that is in contrast to a study by Riley
et al. (2000) showing that cord blood antibody titres in Ghanaian
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Fig. 4. Relationship between antibody titres and function with risk of severe malaria. The association between (A) antibody seropositivity and (B) antibody-mediated function
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infants persisted for a long duration in infants who had antibody
levels above the median O.D. level at birth compared with those
below the median. However, results similar to ours have been
reported from studies of viral infections that demonstrated a rapid
postnatal decline of maternally transferred antibodies against
rubella (Cloonan et al., 1970), parainfluenza type 3 and influenza
A2 (Cloonan et al., 1971) in children with high titres at birth com-
pared with infants with low initial titres. IgG sub-class antibodies
against merozoite antigens have also been reported to decay faster
than their expected theoretical half-life in older children
(Kinyanjui et al., 2007).
We speculate that the rate of decay of maternal antibodies may
have been influenced by the presence of sub-patent infections.
Moderate to high maternal antibody titres may have a masking
effect on infections in infants and this could contribute to the rapid
decay of circulating antibodies. On the other hand, infections in the
presence of low titre maternal antibodies could result in serocon-
version and persistence of antibody titres (Riley et al., 2001).
Detection of asymptomatic infections in our study was not com-
prehensive as sampling was undertaken only once every 3 months.
The distribution of different IgG subtypes could also affect the
rate of antibody decline. For instance, IgG3 is more rapidly
degraded than other isotypes (Spiegelberg, 1974). In other infec-
tions, factors such as nutritional status of the infant, breastfeeding,
environmental factors and the presence of other concurrent infec-
tions during infancy have not been shown to influence the kinetics
of antibody decay (Caceres et al., 2000) but their effect on malaria-
specific maternal antibodies is not known.
We found that anti-merozoite antibodies in cord blood were not
associated with parity, maternal age, birth weight or gestational
age. In contrast, other studies demonstrated a positive relationship
between parity and placental malaria infection (Ricke et al., 2000;
Mayor et al., 2011) with increased levels of total IgG to var2CSA
and merozoite antigens. Multiple factors are thought to influence
the transplacental transfer of antibodies and may account for this
disparity. These include maternal factors such as differences in
maternal titres which vary depending on the antigen, IgG subclass
distribution, nature of antigen tested, timing of exposure to anti-
gens during pregnancy and the duration of this exposure
(Palmeira et al., 2012). Varying analytical approaches are also
applied to the study of maternal antibodies; some studies use cord
blood antibody levels as a proxy measure of the efficacy of
transplacental antibody transfer while others consider the ratio
of antibodies in the mother to infant (Palmeira et al., 2012). We
did not have data on placental malaria, HIV infection, IPTp or use
of insecticide-treated bed nets, all of which may have an impact
on antibody levels.
In summary, we found that cord blood IgG activity in the ADRB
assay was strongly associated with lower odds of developing sev-
ere malaria in the first 9 months of life. Although larger studies
are needed, these data suggest that ADRB could be useful for the
identification of targets of protective antibodies that could be
translated to the clinic as candidate vaccines for infants and young
children who are most susceptible to death due to severe malaria.
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